Merck (MRK) Announces FDA Acceptance of Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar
Go back to Merck (MRK) Announces FDA Acceptance of Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar| Merck & Co. (NYSE: MRK) | Delayed: 146.88 +1.97 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.91 | 52 Week High | $65.46 | |||
| Open | $145.74 | 52 Week Low | $47.97 | |||
| Day High | $147.40 | P/E | 99.92 | |||
| Day Low | $145.32 | EPS | $1.47 | |||
| Volume | 3,552,114 | |||||
